Related Experiment Videos
Insulin glulisine
1Medical Information Department, Prous Science, Barcelona, Spain.
Drugs of Today (Barcelona, Spain : 1998)
|September 30, 2005
Summary
Insulin glulisine, a rapid-acting insulin analog, offers improved glycemic control for diabetes patients. It effectively manages postmeal glucose levels with a safety profile comparable to regular human insulin.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Conventional insulin therapy in diabetes can be limited in achieving tight glycemic control, increasing the risk of long-term complications.
- Recombinant insulin analogs represent advancements in diabetes management.
- Insulin glulisine is a novel rapid-acting insulin analog designed for improved pharmacokinetic properties.
Purpose of the Study:
- To review the clinical efficacy and safety of insulin glulisine.
- To compare insulin glulisine's profile with regular human insulin.
Main Methods:
- Review of current clinical data on insulin glulisine.
- Analysis of pharmacokinetic and pharmacodynamic properties.
- Evaluation of safety and efficacy in type 1 and type 2 diabetes.
Main Results:
- Insulin glulisine demonstrates faster absorption, quicker onset, and shorter duration compared to regular human insulin.
- Effective postprandial glucose control in both type 1 and type 2 diabetes without increased hypoglycemia risk.
- Equivalent glucose-lowering effect per unit compared to regular human insulin.
Conclusions:
- Insulin glulisine offers a valuable therapeutic option for diabetes management.
- Its pharmacokinetic profile allows flexible administration timing (pre- or post-meal).
- Favorable safety profile supports its use in clinical practice.